Z-1215-2022 Class II Ongoing

Recalled by Becton, Dickinson And Company, BD Biosciences — San Jose, CA

FDA device recall Z-1215-2022 was initiated by Becton, Dickinson And Company, BD Biosciences on Mar 25, 2022 and is designated Class II. Reason for recall: Anti-Kappa APC & Anti-Kappa PE analyte reagents may exhibit uncharacteristic flow profiles. The recall status is ongoing. Affected quantity: 199 units.

Recall details

Product Type
Devices
Report Date
Jun 8, 2022
Initiation Date
Mar 25, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
199 units

Product description

BD Anti-Kappa PE (Cat. No. 346587) is an analyte specific reagent for the Anti-Kappa antibody, which specifically recognizes the kappa light chains of human immunoglobulins. Anti-Kappa is used for in vitro identification of cells expressing the kappa light chains using flow cytometry.

Reason for recall

Anti-Kappa APC & Anti-Kappa PE analyte reagents may exhibit uncharacteristic flow profiles.

Distribution pattern

Worldwide distribution - US Nationwide distribution in the states of AL, CA, CO, DC, DE, FL, IA, IL, IN, LA, MA, MD, ME, MI, MN, MO, NC, ND, NY, OH, OK, PA, TN, TX, UT, VA, WA, WI, WV and the country of Taiwan.

Code information

Lot # 1228977; UDI: 00382903465873

Source

Dataset
openFDA device recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for Z-1215-2022
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for Z-1215-2022. Report a data issue: hello@regdatalab.com.